Immunology Faculty Member - Mikael Pittet, MD

Mikael Pittet, MD

Massachusetts General Hospital
Simches Research Building
185 Cambridge Street, Room 5228
Boston, MA 02114
Tel: 617-643-6285
Fax: 617-643-6133
Email: mpittet@mgh.harvard.edu
Visit my lab page here.



My laboratory focuses on uncovering knowledge gaps on the interactions between the immune system and cancer and defining immunotherapies that are effective against a broad range of tumors. To do so, we study various immune cells, including cytotoxic T cells, regulatory T cells, macrophages, monocytes, neutrophils and dendritic cells.

Over the past several years, we have divided our to address both fundamental and translational research questions. In our fundamental studies, we started to address the origins of myeloid cells that accumulate in tumors and other disease sites, the capacity of tumors to hijack myeloid and other cells remotely, and the ability of some myeloid cells to mediate tumor suppressive functions. In our translational studies, we started to address how to make tumors responsive to immunotherapy by harnessing both lymphoid and myeloid cells, and how to use high-resolution imaging to uncover the pharmacokinetics and pharmacodynamics of immunotherapeutic drugs in real-time in vivo.

We collaborate with several immunology programs at Harvard Medical School, Massachusetts General Hospital, Massachusetts Institute of Technology and outside Boston.



Last Update: 6/18/2018



Publications

For a complete listing of publications click here.

 


 

Engblom C, Pfirschke C, Zilionis R, da Silva Martins J, Bos SA, Courties G, Rickelt S, Severe N, Baryawno N, Faget J, Savova V, Zemmour D, Kline J, Siwicki M, Garris C, Pucci F, Liao HW, Lin YJ, Newton A, Yaghi OK, Iwamoto Y, Tricot B, Wojtkiewicz GR, Nahrendorf M, Cortez-Retamozo V, Meylan E, Hynes RO, Demay M, Klein A, Bredella MA, Scadden DT, Weissleder R, Pittet MJ. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science. 2017; 358:6367; eaal5081.

Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ. In vivo imaging reveals a tumor-associated macrophage mediated resistance pathway in anti-PD-1 therapy. Science Translational Medicine. 2017; 9; eaal3604

Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, Alvarez D, Sprachman M, Evavold C, Magnuson A, von Andrian UH, Glatz K, Breakefield XO, Mempel TR, Weissleder R, Pittet MJ. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 2016; 352:242

Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier Colame V, Newton A, Redouane Y, Lin Y-J, Woljtkiewicz G, Iwamoto Y, Mino-Kenudson M, Huynh TG, Hynes RO, Freeman GJ, Kroemer G, Zitvogel L, Weissleder R, Pittet MJ. Tumor sensitization to checkpoint blockade therapy by immunogenic chemotherapeutics. Immunity. 2016; 44:343

Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nature Reviews Cancer. 2016; 16:447

Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nature Materials. 2014; 13:125



© 2016 President and Fellows
of Harvard College